Abstract 134P
Background
Ivonescimab (ivo, AK112/SMT112) is a bispecific antibody against PD-1 and VEGF that demonstrates cooperative binding. The HARMONi-A trial aimed to evaluate the efficacy and safety of ivo combined with chemo versus chemo and placebo in pts with EGFRm+ NSCLC previously treated with EGFR tyrosine kinase inhibitor (TKI) therapy. The current analysis evaluated the IC PFS of patients who received ivo vs. placebo with chemo on the two arms of HARMONi-A.
Methods
Pts were randomized 1:1 with stratification by exposure to third-generation EGFR-TKI (yes/no) and presence of brain metastases (BMs) at baseline (yes/no) to receive ivo (20 mg/kg) plus pemetrexed (500 mg/m2)/carboplatin (AUC 5) or placebo with same chemo every 3 weeks x 4 cycles followed by maintenance therapy of ivo or placebo with pemetrexed. Overall PFS by independent radiologic review committee (IRRC) was the primary endpoint. Brain scans were performed in all pts at baseline and progression and, for pts with baseline BMs, at scheduled assessments until progression. IC PFS was defined as time from random assignment until date of objective IC progression or death from any cause in the absence of known IC progression.
Results
A total of 322 pts were randomized (161 to each arm); 21.7% vs 23.0% of pts had baseline BMs in the ivo and placebo arms, respectively. As of March 10, 2023, median (med) follow up time was 7.9 months (mo). Pts assigned to ivo with chemo demonstrated a significantly superior PFS by IRRC compared to placebo with chemo (med 7.1 vs 4.8 mo; HR 0.46 [0.34, 0.62], P < 0.0001); overall PFS was improved in pts without BMs (HR 0.48 [0.34-0.69]) and those with baseline BMs (HR 0.40 [0.22-0.73]). IC PFS with ivo/chemo was significantly improved compared to placebo/chemo in the intent-to-treat population (med not reached in either arm; HR 0.39 [0.24, 0.64], p < 0.001) and in pts with BMs at baseline (med 8.4 vs 5.4 mo; HR 0.33 [0.15, 0,74], p = 0.005).
Conclusions
In addition to improving previously reported efficacy endpoints on HARMONi-A, ivo added to chemo significantly improved IC PFS among pts with advanced EGFRm+ NSCLC whose disease had progressed on prior EGFR TKI therapy.
Clinical trial identification
NCT05184712.
Legal entity responsible for the study
Akeso Biopharma.
Funding
Akeso Biopharma.
Disclosure
L. Zhang: Financial Interests, Institutional, Research Grant, Research support: Hengrui, BeiGene, Xiansheng, Eli Lilly, Novartis, Roche, Hansoh, Bristol Myers Squibb Pharma; Financial Interests, Institutional, Speaker, Consultant, Advisor: Beigene, Xiansheng Pharma, MSD. H.(West: Financial Interests, Institutional, Full or part-time Employment: Summit Therapeutics; Non-Financial Interests, Institutional, Member of Board of Directors, Founder, previously President & CEO, currently a member of the Board of Directors: Global Resource for Advancing Cancer Education (GRACE). W. Li: Financial Interests, Personal, Full or part-time Employment: Akeso Biopharma. Y. Xia: Financial Interests, Institutional, Full or part-time Employment: Akeso Biopharma; Financial Interests, Institutional, Member of Board of Directors: Akeso Biopharma. All other authors have declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
Resources:
Abstract
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
Resources:
Abstract
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
Resources:
Abstract
36P - Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Luigi Liguori
Session: Poster Display session
Resources:
Abstract
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
Resources:
Abstract
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
Resources:
Abstract
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
Resources:
Abstract
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
Resources:
Abstract
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract